Piperazine indazole glucocorticoid receptor antagonists
US12098144B2 · kind B2 · utility
0Cited by
20References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2022 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Dec 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.